Keywords: Juvenile arthritis, Pfizer, Amgen, Enbrel, Etanercept

Study identifies factors linked with better medication response for treatment of juvenile arthritis

Article | 07 November 2011

Print This

Among patients with juvenile idiopathic arthritis (JIA) who initiated treatment with the drug etanercept (Pfizer and Amgen’s blockbuster ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in